Quantification of disease-associated RNA tandem repeats by nanopore sensing

This paper presents a single-molecule nanopore sensing strategy using RNA:DNA nanostructures to directly quantify and discriminate disease-associated RNA tandem repeat expansions with 18-nucleotide resolution, offering a promising tool for diagnosing repeat expansion disorders like DM1, DM2, and CCHS1 in complex biological samples.

The Gist

Imagine your body's genetic code (DNA) is like a massive instruction manual for building and running a human being. Sometimes, due to a glitch, a specific sentence in that manual gets stuck on repeat. Instead of saying "Build a muscle," it might say "Build a muscle, build a muscle, build a muscle..." over and over again.

In some diseases, like Myotonic Dystrophy or Congenital Central Hypoventilation Syndrome, this "stutter" happens in the RNA (the copy of the manual used to build proteins). If the stutter is short, it's harmless. But if it gets too long—like a broken record skipping for hundreds of times—it poisons the cell and causes severe illness.

The problem for doctors is that counting these skips is incredibly hard. Current methods are like trying to count the words in a paragraph by photocopying it first; the copying machine (PCR) often gets confused by the repetition, skips words, or adds extra ones, giving you the wrong count.

Here is how the scientists in this paper solved the problem:

1. The "Molecular Barcode" Strategy

Instead of trying to read the messy, repetitive RNA directly, the scientists built a tiny, custom-made "scaffold" around it. Think of it like putting a repetitive paragraph into a custom-made book cover that has specific features.

• The Book Cover (Nanostructure): They took the RNA and wrapped it with short pieces of DNA.
• The Barcodes: They attached little "flags" (called streptavidin) to specific spots on this DNA cover. These flags act like a barcode. For example, a flag at the start and end might mean "This is a 12-repeat sample," while flags in the middle might mean "This is a 51-repeat sample." This helps the machine know which RNA it is looking at.
• The Repeat Counter: The most important part is how they counted the repeats. They used a special DNA "tape measure" that sticks to the repetitive RNA. The longer the repeat, the more tape measures can stick to it. Each tape measure holds two flags. So, a short repeat holds a few flags; a long, disease-causing repeat holds many flags.

2. The "Toll Booth" (Nanopore Sensing)

Now, how do you count the flags? The scientists used a nanopore, which is essentially a microscopic tunnel (a hole in a membrane) so small that only one molecule can fit through at a time.

• The Process: They apply an electric current to pull the RNA "book" through this tiny tunnel.
• The Signal: As the RNA passes through, it blocks the flow of electricity (ions), creating a dip in the current.
  • The body of the RNA creates a steady, shallow dip.
  • The barcode flags create small, sharp spikes in the dip.
  • The repeat flags (the ones stuck to the stuttering part) create a huge, deep spike.

The Analogy: Imagine driving a car through a toll booth.

• The car itself makes a small noise as it passes.
• If you have a few toll passes (barcodes), you hear a few small "beeps."
• But if you are carrying a massive pile of heavy cargo (the disease-causing repeats with all their flags), the car hits the ground harder, creating a massive thud.

By measuring the size of that "thud" (the depth of the electrical spike), the machine can instantly tell you exactly how many repeats are on that RNA molecule.

3. Why This is a Game-Changer

• No Copying Needed: Unlike old methods, this doesn't need to copy the DNA/RNA first. It reads the original molecule directly, so it doesn't get confused by the repetition.
• Super Precise: They showed they could tell the difference between a harmless 20 repeats and a dangerous 26 repeats (a difference of just 6 "letters"). That's like distinguishing between a sentence with 20 words and one with 26 words, even if they are all the same word repeated.
• Works in the Real World: They tested this not just on clean lab samples, but on RNA extracted from actual human cells (a "soup" of millions of different molecules). Their method found the specific "stuttering" RNA needle in the haystack without getting lost.

The Bottom Line

This new tool is like a high-tech, single-molecule counter that can look at a single strand of RNA, count exactly how many times a genetic "stutter" occurs, and tell a doctor if a patient has a dangerous disease or is safe. It opens the door to better diagnostics and understanding of these tricky genetic disorders without the errors of previous methods.

Technical Summary

1. Problem Statement

Repeat Expansion Disorders (REDs) are a class of over 60 neurological and neuromuscular diseases caused by the expansion of short tandem repeats (STRs) in DNA, which are transcribed into RNA. Accurate quantification of these repeat lengths is critical for diagnosis and understanding disease severity, as the number of repeats often correlates with onset and prognosis.

Current methods face significant limitations:

• PCR-based methods: Suffer from amplification bias (slippage during polymerization) and preferential amplification of wild-type alleles, leading to inaccurate sizing of large expansions.
• Short-read sequencing (Illumina): Cannot span large repetitive regions, resulting in incomplete or ambiguous data.
• Long-read sequencing (PacBio/Nanopore): While capable of spanning repeats, they suffer from high error rates in homopolymer regions, require specialized base-calling algorithms, and often demand high input material, limiting their immediate clinical utility.
• Reverse Transcription (RT): Converting RNA to cDNA introduces biases, particularly for RNAs with complex secondary structures (e.g., hairpins formed by CUG/CCUG repeats).

There is a clear need for an amplification-free, single-molecule method that can directly quantify RNA tandem repeats with high resolution in complex biological samples.

2. Methodology

The authors developed a novel strategy combining RNA:DNA nanotechnology with solid-state nanopore sensing. The core workflow involves:

• Target Selection: The study focused on repeats associated with:
  • Myotonic Dystrophy Type 1 (DM1): CUG trinucleotide repeats.
  • Myotonic Dystrophy Type 2 (DM2): CCUG tetranucleotide repeats.
  • Congenital Central Hypoventilation Syndrome-1 (CCHS1): GCN trinucleotide repeats.
• Nanostructure Assembly:
  • RNA transcripts containing specific repeat lengths were generated via in vitro transcription from DNA plasmids.
  • These RNA molecules were hybridized with complementary single-stranded DNA oligonucleotides (~40 nt) to form an RNA:DNA nanostructure.
  • Barcoding: Specific DNA "dumbbell" structures were attached to the nanostructure backbone at defined positions to create a unique current signature (a "barcode") for identifying the transcript type.
  • Repeat Labeling: The tandem repeat regions were targeted by hybridizing multiple complementary DNA oligonucleotides. These oligonucleotides were designed with overhangs to bind streptavidin molecules.
• Nanopore Sensing:
  • The assembled RNA:DNA nanostructures were driven through a solid-state nanopore (8–15 nm diameter) by an applied voltage.
  • As the molecule translocates, it partially blocks the ionic current.
  • Signal Generation:
    • The RNA:DNA backbone produces a baseline current drop.
    • The barcode streptavidins produce distinct, smaller current spikes (e.g., a "1111" pattern).
    • The repeat-sensing region produces a prominent, deeper current spike. The depth and area of this spike are proportional to the number of streptavidin molecules bound, which in turn correlates to the number of hybridized oligonucleotides and thus the repeat length.

3. Key Contributions

• Amplification-Free Quantification: The method bypasses PCR and reverse transcription, eliminating associated biases and errors.
• Single-Molecule Resolution: It enables the direct counting of repeat units on individual RNA molecules.
• High Resolution: The system achieves a resolution of 18 nucleotides (equivalent to 6 trinucleotide repeats), sufficient to distinguish between wild-type and pathogenic alleles.
• Multiplexing Capability: By using distinct barcode patterns, different transcript variants can be distinguished within the same nanopore measurement.
• Complex Sample Compatibility: The method was successfully demonstrated in total human RNA extracted from cell lines, proving its ability to detect low-abundance targets amidst a complex background without prior enrichment.

4. Key Results

• DM1 (CUG Repeats):
  • Successfully discriminated between wild-type sizes (12, 24, 30 repeats) and a pathogenic size (51 repeats).
  • The median current spike depth increased linearly with repeat number (0.09 nA for 12 repeats vs. 0.61 nA for 51 repeats).
  • Statistical analysis (Welch's t-test) showed highly significant separation between all groups ($p < 0.001$).
• DM2 (CCUG Repeats):
  • Demonstrated detection of tetranucleotide repeats using a similar labeling strategy with (CAGG)8 oligonucleotides.
  • Successfully identified the repeat array despite potential interruptions in the sequence.
• CCHS1 (GCN Repeats):
  • Distinguished between the wild-type allele (20 repeats) and the pathogenic allele (26 repeats).
  • Achieved a 6-repeat resolution (18 nt), with a median current difference of 0.15 nA vs. 0.8 nA ($p = 9.3 \times 10^{-9}$).
• Cell Line Model (DM1 in Total RNA):
  • Transfected HEK293T cells with a plasmid containing CTG repeats.
  • Extracted total RNA and assembled nanostructures directly from the lysate.
  • Successfully detected the CUG-repeat containing mRNA (approx. 2.1 nM concentration) against a background of abundant non-target RNA, confirming the method's specificity and sensitivity in a biological context.

5. Significance

This work presents a transformative approach for the diagnosis and study of Repeat Expansion Disorders:

• Clinical Diagnostics: It offers a potential diagnostic tool that avoids the pitfalls of PCR bias and sequencing errors, providing accurate sizing of repeats directly from RNA. This is crucial for diseases where repeat length determines clinical outcome (e.g., DM1, CCHS1).
• Therapeutic Development: Since RNA toxicity is a central mechanism in many REDs, this platform allows for the study of repeat biology at the single-molecule level, aiding in the development of gene-modifying therapies.
• Scalability: The method is compatible with complex biological samples and can be parallelized using multi-nanopore chips, suggesting a path toward high-throughput clinical screening.
• Versatility: While demonstrated on CUG, CCUG, and GCN repeats, the platform is adaptable to other STRs (including those with high GC content or interruptions) provided the hybridization conditions are optimized.

In summary, the authors have established a robust, amplification-free nanopore sensing platform that quantifies disease-associated RNA tandem repeats with high precision, offering a significant advancement over current genomic and transcriptomic technologies.